2076975 2077203
최종편집 2024-04-15 22:42 (월)
Korea to reimburse levofloxacin and doxycycline for children with Mycoplasma pneumonia
상태바
Korea to reimburse levofloxacin and doxycycline for children with Mycoplasma pneumonia
  • Jaehoon SongㆍHyeokgi Lee, Newsmp
  • 승인 2023.12.21 15:19
  • 댓글 0
이 기사를 공유합니다

Off-label drug coverage to be applied from 20

[Newsmp] The Korean government has established new coverage standard for Levofloxacin injection drug Cravit Inj. (Jeil Pharmaceutical) and oral drug Levofexin (Il Dong Pharmaceutical), and expanded coverage standard for Doxycycline Vibramycin-N (Pfizer), in response to the spread of Mycoplasma pneumonia.

The Ministry of Health and Welfare announced Monday an administrative notice of ‘Notice of the Review Results of a Healthcare Service Claim’ and said it will take effect on December 20.

According to the ordinance, Levofloxacin injection is covered by insurance when administered to treat macrolide-resistant Mycoplasma pneumonia, within the scope of its approved indications and beyond.

Levofloxacin injections are now covered for macrolide-resistant Mycoplasma pneumonia in children who have not improved after 3 days of macrolide antibiotics. For children under 5 years old, the dose is 16 to 20 mg/kg/day, every 12 hours (maximum 750 mg/day). For children 5 years of age or older, the dose is 8 to 10 mg/kg/day, once a day (maximum 750 mg/day). The administration period is within 7 to 14 days.

Doxycycline drugs are also covered by insurance for the treatment of macrolide-resistant Mycoplasma pneumonia, in addition to the existing coverage criteria, even if it is used off-label.

Doxycycline formulations are approved for administration in children under 12 years of age who do not achieve symptom improvement after 3 days of macrolide antibiotic therapy. The given dosage is 4mg/kg/day, divided into two doses (maximum 200mg/day), with a treatment duration of 7 to 14 days.

Furthermore, Levofloxacin oral preparations are reimbursed for the treatment of macrolide-resistant Mycoplasma pneumonia, even when used off-label.

As with other approved drugs, the eligible are children diagnosed with Mycoplasma pneumonia who fail to achieve symptom improvement after 3 days of treatment with macrolide antibiotics. For children under 5 years of age, the dosage is 16-20 mg/kg per day, divided into two doses (maximum 750 mg/day). For children 5 years of age and older, the dosage is 8-10 mg/kg per day, given once daily (maximum 750 mg/day). For adolescents with mature musculoskeletal systems, the dosage is 500 mg per day, given once daily. The treatment period is 7-14 days.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.